About Enara Bio
Enara Bio is a company based in Oxford (United Kingdom) founded in 2016. Enara Bio has raised $84.05 million across 5 funding rounds from investors including RA Capital, The Francis Crick Institute and Pfizer Ventures. The company has 38 employees as of December 31, 2021. Enara Bio offers products and services including EDAPT Platform, Dark Antigens, and TCR-based Immunotherapies. Enara Bio operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Oxford, United Kingdom
- Employees 38 as on 31 Dec, 2021
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Enara Bio Limited
- Date of Incorporation 08 Nov, 2016
- Jurisdiction OXFORD, OXFORDSHIRE, UNITED KINGDOM
-
Annual Revenue
$5.89 M (USD)-14as on Dec 31, 2022
-
Net Profit
-$13.33 M (USD)-27as on Dec 31, 2022
-
EBITDA
-$17.24 M (USD)-21as on Dec 31, 2022
-
Total Equity Funding
$84.05 M (USD)
in 5 rounds
-
Latest Funding Round
$32.5 M (USD), Series B
Oct 03, 2024
-
Investors
RA Capital
& 5 more
-
Employee Count
38
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Enara Bio
Enara Bio offers a comprehensive portfolio of products and services, including EDAPT Platform, Dark Antigens, and TCR-based Immunotherapies.
Technology for discovering cancer-specific Dark Antigens.
Novel antigens used in developing immunotherapies.
Treatments targeting cancer through T-cell biology.
People of Enara Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Enara Bio
Enara Bio has successfully raised a total of $84.05M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $32.5 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Enara Bio
Enara Bio has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include RA Capital, The Francis Crick Institute and Pfizer Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in multiple sectors
|
Locked | Locked | Locked | |
|
Venture capital investments are managed by Pfizer-backed firm since 2004.
|
Locked | Locked | Locked | |
|
Venture capital funding is provided by Samsara BioCapital in California.
|
Locked | Locked | Locked |
Investor details for Enara Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Enara Bio
Investment portfolio details for Enara Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Enara Bio
Detailed financials for Enara Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Enara Bio Comparisons
Peer comparison for Enara Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Enara Bio
Enara Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of Enara Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Enara Bio
Complete news archive for Enara Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Enara Bio
Enara Bio was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Enara Bio is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Kevin Pojasek is the current CEO of Enara Bio.
Enara Bio is a funded company, having raised a total of $84.05M across 5 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Enara Bio is 38.
Annual revenue of Enara Bio is $5.89M as on Dec 31, 2022.
Enara Bio was founded in 2016 in Oxford, United Kingdom, within the biotechnology sector focused on cancer immunotherapy. Operations center on identifying and characterizing targets such as dark antigens from genomic dark matter and those presented by the cancer-specific MR1 receptor. Proprietary TCR-directed T-cell therapies are offered to address tumor heterogeneity, alongside cancer vaccines for polyclonal autologous ex vivo T-cell stimulation.
Enara Bio's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Enara Bio offers EDAPT Platform, Dark Antigens, and TCR-based Immunotherapies.
Enara Bio has 6 investors. Key investors include RA Capital, The Francis Crick Institute, Pfizer Ventures, M-Ventures, and Samsara BioCapital.
The valuation of Enara Bio is $61.61M as of May 2021.